Project Details
Description
Narrative
Our study will define the immunogenicity of Covid-19 booster vaccinations in patients with a malignant diagnosis.
The first study cohort will focus on detectable immunogenicity as defined by standard antibody assays as well
as T cell and viral neutralization assays from FDA authorized booster dosing in patients with a cancer diagnosis,
while the second study cohort will involve a randomized study to assess the superiority of a “switch” versus
conventional booster strategy. These studies will provide pivotal information to best protect our most vulnerable
patient populations with a cancer diagnosis.
Status | Active |
---|---|
Effective start/end date | 12/31/89 → 6/30/22 |
Funding
- National Cancer Institute: $431,130.00
- National Cancer Institute: $250,747.00
- National Cancer Institute: $167,791.00
- National Cancer Institute: $237,147.00
- National Cancer Institute: $2,916,911.00
- National Cancer Institute: $2,916,911.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.